This study describes a clinical case of a 71-year-old male with a history of ischemic cardiomyopathy after left ventricular assist device (LVAD) endocarditis caused by methicillin-resistant Staphylococcus epidermidis (MRSE) and a rare linezolidresistant Streptococcus sanguinis strain (MIC, 32 g/ml). The patient received courses of several antimicrobial agents, including linezolid for 79 days. The S. sanguinis strain had mutations in the 23S rRNA (T2211C, T2406C, G2576T, C2610T) and an amino acid substitution (N56D) in L22 and exhibited cross-resistance to ribosome-targeting agents.
L
inezolid has been widely prescribed to treat serious infections caused by multidrug-resistant (MDR) Gram-positive pathogens since its clinical introduction as the first oxazolidinone in 2000 (1) . Linezolid is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated and uncomplicated skin and skin structure infections and nosocomial and community-acquired pneumonia caused by susceptible organisms (2) . Linezolid also has an FDA indication for the treatment of vancomycin-resistant Enterococcus faecium (VRE) infections (including bacteremia) (2) .
This oxazolidinone alters protein synthesis by interacting with the 50S ribosomal subunit, and recent data suggest that this drug binds to the A site of the peptidyl-transferase center (PTC) of bacterial ribosome, interfering with the positioning of aminoacyl-tRNA and resulting in protein synthesis inhibition (3) . Although the prevalence of linezolid resistance among Gram-positive organisms remains low among surveillance clinical isolates (1), the resistance mechanisms detected have been comprised mostly of mutations in domain V of 23S rRNA, but alterations in the ribosomal proteins L3 and L4 have also been associated with decreased susceptibility (3, 4) . Moreover, a more recent resistance mechanism, cfr, has been recognized. cfr encodes a methyltransferase that catalyzes the posttranscriptional methylation of nucleotide A2503 in the 23S rRNA, causing decreased susceptibility to phenicol, lincosamide, oxazolidinone, pleuromutilin, and streptogramin A (PhLOPS A ) compounds (4) .
Overall, staphylococci and enterococci represent the vast majority of linezolid-nonsusceptible clinical pathogens reported (3). Although published reports have described the in vitro selection of laboratory strains of streptococci displaying decreased susceptibility to linezolid due to mutations in the PTC (5, 6), only two clinical cases of linezolid-resistant streptococcal isolates (Streptococcus pneumoniae and Streptococcus oralis) have been described to date (1, 7, 8 (10) . MIC interpretations were based on the CLSI M100-S23 document (10) or the FDA package insert (tigecycline) (21) . The presence of cfr and mutations in the 23S rRNA and ribosomal proteins (L3, L4, and L22) was investigated by PCR and sequencing. Primers utilized were as follows: L3-F, ATGACCAAAGGAATCTTA GGG; L3-R, TTAGCACCTGGTACGTTACC; L4-F, AGCGATGC AGTATTTGGTATCG; L4-R, AAATTCATTATGCAAGAACC; L22-F, GAACTCAGCTGTAGCTAACGC; L22-R, TTCTGCAAC AGCTACAGTGATG. The PCR conditions were as follows: initial denaturation at 95°C (5 min); 35 cycles of 94°C (30 s), 55°C (30 s), and 72°C (1 min); and final extension at 72°C (5 min). Amplicons were sequenced on both strands. 23S rRNA and ribosomal proteins obtained were compared to those from wild-type S. sanguinis ATCC 10556 using the Lasergene software package (DNAStar, Madison, WI). This isolate was also screened for vga(ABCD), lsa(ABC), and tetracycline [tet(KLMO)] genes by PCR (11) . The S. sanguinis strain was subjected to serial daily passage on drug-free blood agar plates for 60 days, followed by susceptibility testing. Growth curves were performed in duplicate for the index and wild-type ATCC 10556 strains, as previously described (12) .
In April 2011, a 71-year-old male patient was diagnosed with LVAD endocarditis caused by MRSE, and aztreonam (5-day therapy), gentamicin (5 days), rifampin (5 days), and vancomycin (10 days) were prescribed, followed by daptomycin (25 days) and linezolid (8 days) (April to May 2011) (Fig. 1) . The patient was discharged and continued receiving linezolid (79 days). He was readmitted in July 2011 due to persistent MRSE bacteremia, and vancomycin therapy (3 days) was introduced, while linezolid (3 days) remained. The patient was discharged on linezolid and then switched to doxycycline. The patient was readmitted in September 2011, and blood cultures yielded MRSE, followed by linezolid-resistant S. sanguinis (MIC, 32 g/ml) ( Fig. 1 and Table 1 ). S. sanguinis was cleared, but the MRSE infection persisted, with another positive blood culture in December 2011, despite several (five) changes of peripherally inserted central venous catheters (PICCs) between April and December 2011. In March and May 2012, Pseudomonas aeruginosa was recovered from blood cultures, which cleared later. The patient was discharged but expired in May from further complications.
Linezolid-resistant S. sanguinis also exhibited elevated MIC results for chloramphenicol, clindamycin, tiamulin, tetracycline, doxycycline, and quinupristin-dalfopristin (Table 1) . When tested against other ribosome-targeting agents, the S. sanguinis strain showed susceptible and/or low MIC values for erythromycin and tigecycline. Mutations were observed within the 23S rRNA at positions T2211, T2406, G2576, and C2610 (Escherichia coli numbering of rRNA), and there was an N56D amino acid substitution in L22. Wild-type amino acid sequences were observed for L3 and L4 ( Table 1 ). The S. sanguinis strain was PCR negative for cfr, vga, and lsa genes and positive for tet(M). After 60 days of passage in nonselective medium, passage-derived S. sanguinis strains demonstrated antimicrobial susceptibility profiles equivalent to that of the parent strain ( Table 1 ). The S. sanguinis mutant strain demonstrated a lag phase longer than the control strain, and both growth curves had distinct log and stationary phases (Fig. 2) . In addition, 31228R showed a generation time of approximately 30 min, which was 2-fold longer than that of ATCC 10556 (i.e., ϳ15 min). Among the 23S rRNA mutations observed, G2576T and C2610T are within the PTC and are known to affect the linezolid MIC values and to cause cross-resistance to other ribosome-targeting agents, such as clindamycin, chloramphenicol, streptogramin A, and pleuromutilins (13) (14) (15) (16) . However, strain 31288R was susceptible to erythromycin, which corroborates the fact that this drug interacts with the 50S rRNA exit tunnel wall, and binding is mostly affected by mutations at 23S rRNA residues 2058 and 2059 (17) . Moreover, amino acid substitutions in L22 can result in macrolide resistance, but the ribosomal protein alteration observed here seems to have little effect on erythromycin (18) . It is well known that mutations in the 23S rRNA may affect protein synthesis and confer lethal phenotypes; otherwise, they may confer a high bacterial fitness cost (16) . Although the resistance phenotype displayed by strain 31228R seemed to be stable based on the passaging experiment, the ribosomal mutations and/or the L22 amino acid alteration seemed to adversely affect the growth rate (fitness) of S. sanguinis. However, it is important to mention the limitations of the growth rate experiments, since strains with different backgrounds were utilized and the results observed may have been originated due to factors other than the ribosomal modifications detected. In summary, further experiments are necessary to understand the impact of each 23S rRNA and the L22 amino acid substitution on the susceptibility profile and fitness cost. In addition, any modifications observed in the 23S rRNA may also act as compensatory mutations, as well as the L22 amino acid substitution, since alterations in this protein have not been associated with linezolid resistance due to a more distal position from the PTC (6, 19, 20) . Lastly, the combination of ribosomal modifications observed in this strain appears to affect binding of several ribosome-targeting agents and produce a resistance profile similar to that of Cfr (PhLOPS A ) (4). 
